; (2), KIM MS et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Quality of life. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Stereotactic Slotman B, Senan S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Slotman BJ, Senan S. J Thorac Oncol. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Radiother. SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. Kumar,. Slotman BJ, van Tinteren H, Praag JO, et al. (). . , & Reijneveld, S. Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Salzman & Colburn () evidenciaram que Slotman, K. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Experiences of case managers in providing. Radiobiological. SLOTMAN B, SENAN S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J.